PMID- 25274443
OWN - NLM
STAT- MEDLINE
DCOM- 20150626
LR  - 20240325
IS  - 1939-1676 (Electronic)
IS  - 0891-6640 (Print)
IS  - 0891-6640 (Linking)
VI  - 28
IP  - 5
DP  - 2014 Sep-Oct
TI  - Phase II evaluation of VDC-1101 in canine cutaneous T-cell lymphoma.
PG  - 1569-74
LID - 10.1111/jvim.12429 [doi]
AB  - BACKGROUND: Canine cutaneous T-cell lymphoma (CTCL) is an uncommon disease for 
      which efficacious therapies are lacking. The novel anticancer nucleotide prodrug 
      VDC-1101 (formerly known as GS-9219) has shown efficacy in dogs with multicentric 
      lymphoma. One of the observed adverse effects with this drug was a skin change 
      characterized by hair loss, erythema, and pruritus, implying delivery of VDC-1101 
      to the skin. HYPOTHESIS/OBJECTIVES: The primary study objective was to identify 
      the objective response rate (ORR) to VDC-1101 in canine CTCL; secondary 
      objectives included characterization of progression-free survival (PFS) and 
      adverse events (AEs). ANIMALS: Twelve dogs with chemotherapy-naive or relapsed, 
      histologically and immunohistochemically confirmed CTCL. METHODS: Dogs received 
      VDC-1101 as a 30-minute IV infusion once every 21 days. Prednisone (1 mg/kg PO 
      q48h) was administered concurrently. RESULTS: In 11 evaluable patients, responses 
      included 1 complete response (CR), 4 partial responses (PR), 2 stable disease 
      (SD), and 4 progressive disease for an ORR of 45% and biologic response rate 
      (CR/PR/SD) of 64%. The median PFS was 37.5 days (26 to >399 days), which includes 
      1 durable and ongoing CR (>1 year). Gastrointestinal and hematologic AEs were 
      mild; no dogs developed grade 3 or 4 AEs. Three dogs developed dermatopathies and 
      1 of these dogs was removed from the study as a result of this AE. CONCLUSIONS 
      AND CLINICAL IMPORTANCE: VDC-1101 has activity against canine CTCL and could 
      provide another treatment option in a disease process with a poor prognosis.
CI  - Copyright (c) 2014 by the American College of Veterinary Internal Medicine.
FAU - Morges, M A
AU  - Morges MA
AD  - Flint Animal Cancer Center, Colorado State University, Fort Collins, CO.
FAU - Burton, J H
AU  - Burton JH
FAU - Saba, C F
AU  - Saba CF
FAU - Vail, D M
AU  - Vail DM
FAU - Burgess, K E
AU  - Burgess KE
FAU - Thamm, D H
AU  - Thamm DH
LA  - eng
PT  - Clinical Trial, Phase II
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Vet Intern Med
JT  - Journal of veterinary internal medicine
JID - 8708660
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Purines)
RN  - 0 (rabacfosadine)
RN  - OF5P57N2ZX (Alanine)
SB  - IM
MH  - Alanine/adverse effects/*analogs & derivatives/therapeutic use
MH  - Animals
MH  - Antineoplastic Agents/adverse effects/*therapeutic use
MH  - Dog Diseases/*drug therapy
MH  - Dogs
MH  - Female
MH  - Lymphoma, T-Cell, Cutaneous/drug therapy/*veterinary
MH  - Male
MH  - Purines/adverse effects/*therapeutic use
MH  - Skin Diseases/chemically induced/veterinary
MH  - Skin Neoplasms/drug therapy/*veterinary
MH  - Treatment Outcome
PMC - PMC4895598
OTO - NOTNLM
OT  - Cancer
OT  - Chemotherapy
OT  - Dog
OT  - Mycosis fungoides
EDAT- 2014/10/03 06:00
MHDA- 2015/06/27 06:00
PMCR- 2014/09/01
CRDT- 2014/10/03 06:00
PHST- 2014/02/12 00:00 [received]
PHST- 2014/06/17 00:00 [revised]
PHST- 2014/07/07 00:00 [accepted]
PHST- 2014/10/03 06:00 [entrez]
PHST- 2014/10/03 06:00 [pubmed]
PHST- 2015/06/27 06:00 [medline]
PHST- 2014/09/01 00:00 [pmc-release]
AID - JVIM12429 [pii]
AID - 10.1111/jvim.12429 [doi]
PST - ppublish
SO  - J Vet Intern Med. 2014 Sep-Oct;28(5):1569-74. doi: 10.1111/jvim.12429.